ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2222

Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile

Gregg Silverman1, Macintosh Cornwell1, Peter Izmirly1, Mala Masson1, Jill Buyon1, Doua Azzouz2 and Kelly Ruggles1, 1NYU Grossman School of Medicine, New York, NY, 2NYU Gross School of Medicine, New York, NY

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Lupus nephritis, microbiome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common. These imbalances can range from subtle patterns of dysbiosis to blooms in abundance of individual species that are concordant with clinical disease flares. Based on preliminary longitudinal surveys, more than 40% of Lupus nephritis (LN) flares were concurrent with transient expansions of a pathobiont, Ruminococcus (blautia) gnavus. As the transcriptomic patterns in the cells in our bloodstream can reflect disease activity, we sought to investigate gene expression patterns in groups of lupus patients, with comparisons to healthy controls (HC).

Methods: From a well-characterized cohort, exploratory studies were performed on a selected group of 15 active female SLE patients, based in part on SLEDAI scores > 4. Patients were grouped as without a history of renal involvement (i.e., non-renal) (N=7) or with LN in flare with Urine Protein creatinine ratio >0.5. Based on 16S rRNA fecal microbiota analyses, LN were subsetted as without bloom of individual species (N=4), or with a bloom ( > 20-fold increased from HC, 3-9% abundance) of R. gnavus (N=4). In comparisons with 8 female HC, bulk RNA-seq was completed and after standard QC and filtering, 24,319 genes passed a minimum threshold of 4 reads in >50% samples and were used in downstream analysis.

Results: Unsupervised clustering based on gene expression demonstrated significant separation between SLE samples and HC (Figure 1). While there was no clear distinction between non-renal and renal (i.e., LN) groups, there were striking differences in the group of active LN without detectable gut microbiome blooms vs. active LN with R. gnavus blooms (Figure 2), with 173 upregulated and 13 downregulated genes based on differential expression analysis (padj < 0.05, log2fc > 1). Gene set enrichment analysis (GSEA) identified several significantly altered pathways in the LN flare with blooms compared to no blooms, in highlighting multiple platelet activation pathways in the LN with blooms. In contrast, the LN flares without blooms had significantly higher interferon alpha and interferon gamma signatures.

Conclusion: Our findings document distinct pathways of immune activation in PBMC of LN in flare with concurrent gut blooms of R. gnavus, a commensal that is well-established as expanded in active LN patients, including an independent SLE cohort studied at initial diagnosis without previous treatment. These findings may indicate that in a major subset of patients, LN flares may arise from severe perturbations of intestinal communities associated with a leaky gut, such as R. gnavus. Moreover, R. gnavus gut colonization has been shown in in vivo models to stoke a feed-forward pro-inflammatory response associated with raised autoantibody and anti-bacterial antibody responses. Together, this highlights R. gnavus as a potential causative agent for Lupus flares, in which blooms may induce immune hyperactivation that underlies lupus autoimmune pathogenesis.

Supporting image 1

Figure 1. Principal Component Analysis of bulk RNA-seq libraries from PBMC show significant differences in the representation of genes expressed in 15 female SLE patients and 8 female Healthy Controls. There is also much greater intra-group diversity for the SLE patients.

Supporting image 2

Figure 2. Comparisons of LN flare subgroup with R. gnavus bloom to LN flare without bloom show significant upregulation of 42 genes, based on an adjusted p <0.5 and qvalue <0.5. In GSEA analysis, four genes amongst the most significantly increased expression in blooms are linked to platelet activation.


Disclosures: G. Silverman, None; M. Cornwell, None; P. Izmirly, Momenta/Janssen; M. Masson, None; J. Buyon, None; D. Azzouz, None; K. Ruggles, None.

To cite this abstract in AMA style:

Silverman G, Cornwell M, Izmirly P, Masson M, Buyon J, Azzouz D, Ruggles K. Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lupus-clinical-flares-in-patients-with-gut-pathobiont-blooms-share-a-novel-peripheral-blood-transcriptomic-immune-activation-profile/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-clinical-flares-in-patients-with-gut-pathobiont-blooms-share-a-novel-peripheral-blood-transcriptomic-immune-activation-profile/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology